Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 553-562

  Soerensen, Anne V ^a   Donskov, Frede ^b   Hermann, Gregers G ^c   Jensen, Niels V ^d   Petersen, Astrid ^e   Spliid, Henrik ^f   Sandin, Rickard ^g   Fode, Kirsten ^b   Geertsen, Poul F ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^g PFIZER INC   (United States)

Author keywords

Metastatic renal cell carcinoma; National cohort; Overall survival; Population based study; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DENDRITIC CELL VACCINE; EVEROLIMUS; FLUOROURACIL; INTERLEUKIN 2; INTERLEUKIN 21; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COHORT ANALYSIS; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

METASTATIC RENAL CELL CARCINOMA; NATIONAL COHORT; OVERALL SURVIVAL; POPULATION-BASED STUDY; TARGETED THERAPY;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; DENMARK; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84893710659     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.010     Document Type: Article

References (20)

1. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
2. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
3. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
4. R.J. Motzer, B. Escudier, and S. Oudard et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
5. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
6. H. Schmidt, J. Brown, and U. Mouritzen et al. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial Clin Cancer Res 16 2010 5312 5319
7. M.E. Gore, C.L. Griffin, and B. Hancock et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial Lancet 375 2010 641 648
8. A. Berntsen, R. Trepiakas, and L. Wenandy et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial J Immunother 31 2008 771 780
9. J. Beck, G. Procopio, and E. Bajetta et al. Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings Ann Oncol 22 2011 1812 1823
10. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
11. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
12. L.C. Harshman, W. Xie, and G.A. Bjarnason et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study Lancet Oncol 13 2012 927 935
13. M.E. Gore, C. Szczylik, and C. Porta et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
14. R.M. Bukowski, W.M. Stadler, and D.F. McDermott et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program Oncology 78 2010 340 347
15. D. Shek, B. Tomlinson, M. Brown, A. Brunson, C. Pan, and P.N. Lara Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients Clin Genitourin Cancer 10 2012 93 98
16. T. Wahlgren, U. Harmenberg, and P. Sandström et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008) Br J Cancer 108 2013 1541 1549
17. A. Poprach, Z. Bortlicek, and T. Büchler et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer center, six agents, one database Med Oncol 29 2012 3314 3320
18. D.Y. Heng, M.J. MacKenzie, and U.N. Vaishampayan et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann Oncol 23 2012 1549 1555
19. D.Y. Heng, W. Xie, and M.M. Regan et al. External validation and comparison to other models of the International metastatic renal-cell carcinoma database consortium prognostic model: a population-based study Lancet Oncol 14 2013 141 148
20. N. Kroeger, W. Xie, and J.L. Lie et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC database consortium criteria Cancer 119 2013 2999 3006